Oncology

Targeted Therapies to Further Improve Outcomes

Higher incomes, higher comorbidity scores, and more advanced cancer were associated with outpatient-shopping behavior in Taiwanese patients.

Michael E. Chernew, PhD; Lee N. Newcomer, MD, MHA; and Sandra M. Swain, MD; examine the treatment benefits, cost concerns, and insurance coverage strategies for pertuzumab.

Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs.

Automated phone and mail population outreach resulted in an almost 4-fold increase in the rate of screening for colorectal cancer even without an office visit.

Panelists talk about payment reform models, such as accountable care organizations and bundled payments, as a response to new treatments in oncology.

Panel members are asked to discuss what drives the cost of drugs in cancer care. They also discuss the role companion diagnostics and personalized medicine play in oncology.

AJMC's Co-Editor-in-Chief, Michael E. Chernew, PhD, Lee N. Newcomer, MD, MHA, UnitedHealthcare, and Sandra M. Swain, MD, Washington Cancer Institute, Medstar Washington Hospital Center.